Vaishali Pharma receives multiple orders worth US$ 73.85 million
This order is subject to initial advance payment as per the agreed terms of the contract
This order is subject to initial advance payment as per the agreed terms of the contract
The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
Receives regulatory approval for its molecule ‘Selumetinib’ in India
The company expects the GMP approval from Saudi Food and Drug Authority (SFDA) to soon pave the way for marketing authorizations from the largest market in the GCC region
Dr. Adams brings more than two decades of experience leading the manufacturing of biologic and gene therapies at all stages of development.
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
N-nitroso dimethylamine (NDMA) is a probable human carcinogen and tts effects on humans rely on observational studies.
Clinical studies are expected to start in Q2 2023.
This artificial RNA ligase has higher thermostability than natural RNA ligase
Subscribe To Our Newsletter & Stay Updated